The goal of the real-world study is to evaluate the long-term seizure control outcomes, postoperative complications, long term impact on cognitive, memory function outcomes, quality-of-life measures, and healthcare resource utilization of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) on patients with drug-resistant epilepsy (DRE).
Epilepsy, a complex neurological disorder characterized by recurrent seizures, affects millions of individuals worldwide, challenging both patients and healthcare providers. The main indication for the epilepsy surgery is the drug resistance as per the consensus from the Task Force of the International League Against Epilepsy (ILAE). Traditional open surgery is an established treatment for drug-resistant epilepsy (DRE), but has limitations such as invasiveness and long recovery times. With the significant advancements of technology, the minimally invasive therapeutic approaches have emerged, among which Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT) stands out as a promising intervention. It provides targeted ablation of epileptogenic tissue while preserving healthy brain regions. Understanding MRgLITT's comprehensive value for DRE is of increasing interest. This real-world study aims to comprehensively evaluate the clinical outcomes, safety profiles, and cost-effectiveness of MRgLITT in patients with DRE. The results of this clinical trial protocol are expected to serve as a comprehensive guide for researchers, clinicians, and stakeholders interested in the treatment of DRE using MRgLITT. We believe this study can influence future treatment strategies, leading to improved outcomes and enhanced quality of life for individuals with epilepsy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
150
MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Seizure-freedom rate
Percentage
Time frame: 6-month, 1-year and 2-year after surgery
Seizure frequency reduction
Times/Months
Time frame: 6-month, 1-year and 2-year after surgery
ILAE classification of outcome
International League Against Epilepsy (ILAE) Outcome Scale. The scale ranges from 1 to 6. The higher value indicates more frequency seizures.
Time frame: 6-month, 1-year and 2-year after surgery
Seizure severity
National Hospital Seizure Severity Scale (NHS3). The scale generates a score from 1 to 27. Higher score indicates more severer seizures.
Time frame: 6-month, 1-year and 2-year after surgery
Rate of mild complications
Percentage
Time frame: Within 1 month after surgery
Cognitive function evaluation
Multiple Ability Self-Report Questionnaire (MASQ). The questionnaire ranges from 38 to 190. Higher score indicates more severer cognitive dysfunction.
Time frame: 6-month, 1-year and 2-year after surgery
Memory function evaluation
Memory Functioning Scale Self-Report (MFS-S). The questionnaire ranges from 0 to 42. Higher score indicates more severer memory dysfunction.
Time frame: 6-month, 1-year and 2-year after surgery
The quality of life
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The EuroQol 5 Dimension 5 Level (ED-5Q-5L). The questionnaire ranges from 0 to 100. Higher score indicates better quality of life.
Time frame: 6-month, 1-year and 2-year after surgery
Length of hospital stay
Days
Time frame: Within 1 month after surgery
Rate of reoperations
Percentage
Time frame: 6-month, 1-year and 2-year after surgery
Rate of antiepileptic drug reduction or withdrawn
Percentage
Time frame: 6-month, 1-year and 2-year after surgery